Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Contributed by: PR Newswire

Tags

H-Lundbeck-A/S

More Like This

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine